Last reviewed · How we verify
Montelukast,mometazon froat
This combination blocks leukotriene receptors (montelukast) and reduces airway inflammation via glucocorticoid signaling (mometasone furoate) to treat asthma and allergic rhinitis.
This combination blocks leukotriene receptors and reduces inflammatory mediators in the airways while delivering topical corticosteroid anti-inflammatory effects. Used for Asthma (maintenance therapy), Allergic rhinitis.
At a glance
| Generic name | Montelukast,mometazon froat |
|---|---|
| Sponsor | Istanbul Training and Research Hospital |
| Drug class | Leukotriene receptor antagonist + inhaled corticosteroid combination |
| Target | Cysteinyl leukotriene receptor 1 (CysLT1) and glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Immunology |
| Phase | FDA-approved |
Mechanism of action
Montelukast is a cysteinyl leukotriene receptor antagonist that prevents bronchoconstriction and inflammation triggered by leukotrienes. Mometasone furoate is an intranasal corticosteroid that suppresses local inflammatory responses in the nasal mucosa. Together, they address both systemic and local airway inflammation through complementary mechanisms.
Approved indications
- Asthma (mild to moderate persistent)
- Allergic rhinitis
Common side effects
- Headache
- Pharyngitis
- Nasal irritation
- Tremor (montelukast-associated)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |